GleamWall
中文EN

RZLT Rezolute, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1509261 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY20.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.9%
ROA-61.2%
ROIC (approx.)-60.4%
Asset turnover—

Leverage & solvency

Liabilities / assets10.5%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue————————
R&D expense$12.81M$14.89M$11.41M$14.35M$13.15M$20.86M$15.28M$12.63M
SG&A expense$6.58M$6.67M$5.95M$9.87M$6.67M$4.99M$4.74M$4.45M
Operating income-$19.39M-$21.56M-$17.37M-$24.22M-$19.82M-$25.85M-$20.02M-$17.08M
Net income-$18.49M-$20.49M-$16.17M-$22.77M-$18.15M-$24.39M-$18.91M-$15.73M
EBITDA-$19.38M-$21.55M-$17.36M-$24.21M-$19.81M-$25.84M-$20.02M-$17.07M
EPS (basic)-0.18—-0.16-0.22-0.18—-0.27-0.22
EPS (diluted)-0.18—-0.16-0.22-0.18—-0.27-0.22
Weighted avg. shares (diluted)104.78M—104.04M103.69M103.42M—70.03M69.94M
Balance sheet
Cash & equivalents$8.15M$10.62M$11.24M$11.94M$9.10M$94.11M$14.60M$8.93M
Short-term investments$81.85M$97.19M$109.03M$120.99M$143.10M$73.75M$72.30M$87.61M
Current assets$93.83M$110.51M$122.05M$135.11M$154.71M$171.15M$88.73M$98.69M
PP&E, net$33,000$41,000$49,000$57,000$64,000$72,000$80,000$87,000
Total assets$96.01M$112.85M$125.46M$138.63M$158.66M$175.49M$94.74M$112.01M
Current liabilities$9.46M$11.42M$7.70M$9.53M$10.21M$11.91M$10.53M$10.61M
Total liabilities$10.06M$12.16M$8.62M$10.63M$11.50M$13.36M$12.17M$12.42M
Shareholders' equity$85.95M$100.69M$116.83M$128.00M$147.17M$162.13M$82.57M$99.59M
Shares outstanding96.72M96.41M96.29M95.55M91.04M87.00M60.54M60.53M
Cash flow statement
Operating cash flow-$18.78M-$13.15M-$13.73M-$20.32M-$17.43M-$22.00M-$17.40M-$13.67M
Investing cash flow$15.77M$12.30M$12.28M$22.81M-$68.49M$346,000$23.05M$11.47M
Financing cash flow$552,000$227,000$747,000$356,000$911,000$101.16M$10,000$657,000
Depreciation & amortization$8,000$8,000$8,000$7,000$8,000$8,000$7,000$8,000
Stock-based compensation$3.27M$4.10M$4.42M$3.41M$2.53M$2.37M$1.91M$1.45M

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.